Walleye Capital LLC Sells 494,706 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Walleye Capital LLC cut its position in Perspective Therapeutics, Inc. (NYSE:CATX) by 96.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 18,117 shares of the company’s stock after selling 494,706 shares during the quarter. Walleye Capital LLC’s holdings in Perspective Therapeutics were worth $242,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in Perspective Therapeutics in the third quarter valued at approximately $57,000. US Bancorp DE boosted its position in Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after buying an additional 3,866 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in Perspective Therapeutics in the second quarter valued at approximately $117,000. Point72 DIFC Ltd purchased a new stake in Perspective Therapeutics in the second quarter valued at approximately $118,000. Finally, Intech Investment Management LLC purchased a new stake in Perspective Therapeutics in the third quarter valued at approximately $137,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Stock Down 2.9 %

Shares of CATX stock opened at $3.66 on Wednesday. The business’s fifty day moving average price is $9.38 and its 200 day moving average price is $11.71. Perspective Therapeutics, Inc. has a 1-year low of $2.28 and a 1-year high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The company had revenue of $0.37 million for the quarter. As a group, equities research analysts anticipate that Perspective Therapeutics, Inc. will post -0.88 EPS for the current year.

Analyst Ratings Changes

CATX has been the topic of several recent research reports. UBS Group initiated coverage on Perspective Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective on the stock. Truist Financial initiated coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price (down from $20.00) on shares of Perspective Therapeutics in a research note on Thursday, November 21st. Finally, Oppenheimer reduced their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 22nd. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Perspective Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.14.

Insider Buying and Selling

In related news, Director Heidi Henson bought 25,975 shares of the stock in a transaction dated Wednesday, December 4th. The stock was acquired at an average price of $3.85 per share, for a total transaction of $100,003.75. Following the completion of the purchase, the director now owns 25,975 shares in the company, valued at $100,003.75. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Johan M. Spoor bought 14,500 shares of the stock in a transaction dated Monday, November 25th. The stock was bought at an average price of $3.78 per share, with a total value of $54,810.00. Following the purchase, the chief executive officer now owns 152,072 shares of the company’s stock, valued at approximately $574,832.16. This represents a 10.54 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 67,570 shares of company stock worth $256,789. 3.52% of the stock is owned by company insiders.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.